We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The FDA placed a partial clinical hold on gemcabene in 2004, requesting preclinical data to move forward with an end of phase 2 meeting in dyslipidemia indications.